StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO – Free Report) in a report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
ARCA biopharma Stock Performance
ARCA biopharma stock opened at $1.75 on Wednesday. ARCA biopharma has a fifty-two week low of $1.56 and a fifty-two week high of $2.16. The company has a market cap of $25.38 million, a PE ratio of -4.73 and a beta of 1.16. The business’s 50-day simple moving average is $1.66 and its two-hundred day simple moving average is $1.79.
ARCA biopharma (NASDAQ:ABIO – Get Free Report) last issued its earnings results on Thursday, February 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter.
Hedge Funds Weigh In On ARCA biopharma
About ARCA biopharma
ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
Read More
- Five stocks we like better than ARCA biopharma
- Do ETFs Pay Dividends? What You Need to Know
- Best Bear Market Funds: Top 3 Investment Options to Consider
- About the Markup Calculator
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.